Holzer & Holzer, LLC is investigating Capricor Therapeutics for possible violations of federal securities laws after the FDA reported that Capricor's stem cell treatment for Duchenne muscular dystrophy did not meet Phase 3 trial objectives, contradicting the company's earlier claims. This news caused Capricor's stock price to drop. Investors who suffered losses are encouraged to contact the law firm to discuss potential legal actions. The investigation highlights concerns about the accuracy of Capricor's public statements and the impact on shareholders.
Accenture's stock fell 4.73% to $181.29 after Guggenheim reiterated a Neutral rating, citing that the stock price has outpaced the company's actual business performance. Analysts point to weak customer demand, fewer job postings, and a cautious mid-m...
Thryv Holdings is selling its traditional print directory business for $142 million to focus on business automation software for small and medium businesses. CEO Walsh Joe bought 25,000 shares at $1.80 each, increasing his stake to 788,099 shares, si...
Tempus AI's stock surged 29% in one week, driven by positive analyst commentary and new revenue prospects from reimbursement changes. Goldman Sachs initiated coverage with a Neutral rating and a $75 price target, while technical indicators like a tri...
Seagate Technology's stock is predicted to hit $900 per share on October 27, 2026, coinciding with its fiscal Q1 2027 earnings release. The company has guided revenue around $4.10 billion and non-GAAP EPS near $7.30, following four consecutive quarte...
The Schwab U.S. Dividend Equity ETF (SCHD) remains a strong choice for income-focused investors due to its disciplined approach and low costs. Its recent portfolio update increased holdings in recession-resistant sectors like Healthcare (21%) and Con...
